Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
The association of retinal thickness and vessel skeleton density in diabetic retinopathy
Author Affiliations & Notes
  • Rose Tan
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Anoush Shahidzadeh
    University of Southern California Keck School of Medicine, Los Angeles, California, United States
  • Ana Collazo Martinez
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Xuejuan Jiang
    University of Southern California Keck School of Medicine, Los Angeles, California, United States
  • Amir H Kashani
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Rose Tan None; Anoush Shahidzadeh None; Ana Martinez None; Xuejuan Jiang None; Amir Kashani Carl Zeiss Meditec, Code C (Consultant/Contractor), Carl Zeiss Meditec, Code R (Recipient)
  • Footnotes
    Support  NIH R01EY030564
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4866. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rose Tan, Anoush Shahidzadeh, Ana Collazo Martinez, Xuejuan Jiang, Amir H Kashani; The association of retinal thickness and vessel skeleton density in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2024;65(7):4866.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Evaluating the neuroretinal structure and microvasculature in diabetic retinopathy (DR) is essential to understand the disease pathophysiology. We used optical coherence tomography (OCT) and OCT-angiography (OCTA) images on the macular area to assess the full retinal thickness (FRT) and vessel skeleton density (VSD) and evaluate their relationship in patients with and without DR.

Methods : All subjects were recruited under an IRB-approved protocol. Retinopathy was assessed as mild non-proliferative DR (NPDR) or referable DR (moderate NPDR or worse). FRT and VSD were evaluated on 3x3 mm2 scans (AngioPlex 5000, Carl Zeiss Meditec, Dublin, CA, USA). The FRT was measured from the internal limiting membrane to the outer boundary of the retinal pigment epithelium (Iowa OCT Explorer 3.8, Iowa City, IA). Layer-specific VSD was calculated for the superficial and deep retinal layers by dividing the total blood vessel length with the total area in the skeletonized vessel map as previously described (Kim AY et al., IOVS 2017). The association between parameters were compared among the study groups using one-way ANOVA with Bonferroni post-hoc tests.

Results : Twenty-eight control subjects (39 eyes, 55.3±8.9 yrs), 49 mild NPDR subjects (77 eyes, 58.8±10 yrs), and 26 referable DR subjects (34 eyes, 58.3±10.2 yrs) were evaluated. The FRT was significantly lower in the referable DR group compared to the control group (285±20 vs 295±15 µm, P=0.004), but not between the mild NPDR (290.72±16.28 µm) and control groups (P=0.399), nor between the mild NPDR and referable DR groups (P=0.090). The mean VSD was significantly lower in the referable DR group compared to mild NPDR and control groups (0.145±0.01 vs 0.153±0.01 vs 0.159±0.01, P <0.001). There was a significant correlation between FRT and VSD in control and referable DR groups (R=0.412, P=0.009 and R=0.367, P=0.033, respectively), but not in the mild NPDR group (R=0.223, P=0.051).

Conclusions : VSD was found to be lower in both the mild and referable stages of DR, while FRT was found to be abnormal in the referable stage. Although both VSD and FRT were found to be affected in referable DR eyes, the correlation between the parameters was weaker than in control eyes, suggesting that microvascular and neuroretinal damage do not occur in a strictly proportional manner in DR and that other factors may contribute to the damage at different disease stages.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×